

MECHANISMS OF VASCULAR DISEASE:

A REFERENCE BOOK FOR VASCULAR SPECIALISTS

16

The background of the cover is a textured, reddish-pink color. In the center, there is a large white number '16'. Behind the number, there is a horizontal band representing a cross-section of a blood vessel. The vessel lumen is at the top, and the vessel wall is at the bottom. The vessel wall is shown with a yellowish, wavy texture, representing atherosclerotic plaques. Three green, spherical plaques with orange arrows pointing towards the vessel lumen are shown, illustrating the mechanism of plaque rupture and thrombosis.

EDITED BY ROBERT FITRIDGE AND MATTHEW THOMPSON
COMPLETELY UPDATED EDITION 2011

BARR SMITH PRESS

Mechanisms of Vascular Disease

Mechanisms of Vascular Disease:

A Reference Book for Vascular Specialists

Robert Fitridge

The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia

Matthew Thompson

St George's Hospital Medical School, London, UK



BARR SMITH PRESS

An imprint of
The University of Adelaide Press

Published in Adelaide by

The University of Adelaide, Barr Smith Press
Barr Smith Library
The University of Adelaide
South Australia 5005
press@adelaide.edu.au
www.adelaide.edu.au/press

The University of Adelaide Press publishes peer-reviewed scholarly works by staff via Open Access online editions and print editions.

The Barr Smith Press is an imprint of the University of Adelaide Press, reserved for scholarly works which are not available in Open Access, as well as titles of interest to the University and its associates. The Barr Smith Press logo features a woodcut of the original Barr Smith Library entrance.

© The Contributors 2011

This book is copyright. Apart from any fair dealing for the purposes of private study, research, criticism or review as permitted under the Copyright Act, no part may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission. Address all inquiries to the Director at the above address.

This CIP cataloguing for this work is as follows;

Mechanisms of vascular disease : a reference book for vascular surgeons / Robert Fitridge, Matthew Thompson, [editors].

1. Blood vessels, Diseases.
 2. Blood vessels, Surgery.
-
- I. Fitridge, Robert
 - II. Thompson, M. M.

For the full Cataloguing-in-Publication data please contact National Library of Australia:
cip@nla.gov.au

ISBN (paperback) 978-0-9871718-2-5

Book design: Midland Typesetters

Cover design: Emma Spoehr, based on a diagram by Dave Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre

Paperback edition printed by Griffin Press, South Australia

Table of Contents

Contributors vii

Detailed Contents xi

1. Endothelium 1
Paul Kerr, Raymond Tam, Frances Plane (Calgary, Canada)
2. Vascular smooth muscle structure and function 13
David Wilson (Adelaide, Australia)
3. Atherosclerosis 25
Gillian Cockerill, Qingbo Xu (London, UK)
4. Mechanisms of plaque rupture 43
Ian Loftus (London, UK)
5. Current and emerging therapies in atheroprotection 79
Stephen Nicholls, Rishi Puri (Cleveland, USA)
6. Molecular approaches to revascularisation in peripheral vascular disease 103
Greg McMahon, Mark McCarthy (Leicester, UK)
7. Biology of restenosis and targets for intervention 115
Richard Kenagy (Seattle, USA)
8. Vascular arterial haemodynamics 153
Michael Lawrence-Brown, Kurt Liffman, James Semmens, Ilija Sutalo (Melbourne & Perth, Australia)
9. Physiological haemostasis 177
Simon McRae (Adelaide, Australia)
10. Hypercoagulable states 189
Simon McRae (Adelaide, Australia)
11. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target 201
Sandeep Prabhu, Rahul Sharma, Karlheinz Peter (Melbourne, Australia)
12. Pathogenesis of aortic aneurysms 227
Jonathan Golledge, Guo-Ping Shi, Paul Norman (Townsville & Perth, Australia; Boston, USA)
13. Pharmacological treatment of aneurysms 247
Matthew Thompson, Janet Powell (London, UK)
14. Aortic dissection and connective tissue disorders 255
Mark Hamilton (Adelaide, Australia)
15. Biomarkers in vascular disease 277
Ian Nordon, Robert Hincliffe (London, UK)
16. Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon 295
Martin Veller (Johannesburg, South Africa)
17. SIRS, sepsis and multiorgan failure 315
Vishwanath Biradar, John Moran (Adelaide, Australia)
18. Pathophysiology of reperfusion injury 331
Prue Cowled, Robert Fitridge (Adelaide, Australia)
19. Compartment syndrome 351
Edward Choke, Robert Sayers, Matthew Bown (Leicester, UK)
20. Pathophysiology of pain 375
Stephan Schug, Helen Daly, Kathryn Stannard (Perth, Australia)

21. Postamputation pain 389
Stephan Schug, Gail Gillespie
(Perth, Australia)
 22. Treatment of neuropathic pain 401
Stephan Schug, Kathryn Stannard
(Perth, Australia)
 23. Principles of wound healing 423
Gregory Schultz, Gloria Chin,
Lyle Moldauer, Robert Diegelmann
(Florida, USA)
 24. Pathophysiology and principles of
varicose veins 451
Andrew Bradbury (Birmingham, UK)
 25. Chronic venous insufficiency and leg
ulceration: Principles and vascular
biology 459
Michael Stacey (Perth, Australia)
 26. Pathophysiology and principles of
management of the diabetic foot 475
David Armstrong, Timothy Fisher,
Brian Lepow, Matthew White,
Joseph Mills (Tucson, USA)
 27. Lymphoedema – Principles, genetics
and pathophysiology 497
Matt Waltham (London, UK)
 28. Graft materials past and future 511
Mital Desai, George Hamilton
(London, UK)
 29. Pathophysiology of vascular graft
infections 537
Mauro Vicaretti (Sydney, Australia)
- Index 549

List of Contributors

David G Armstrong
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Vishwanath Biradar
Intensive Care Unit
The Queen Elizabeth Hospital
Woodville, SA
Australia

Matthew Bown
Department of Vascular Surgery
University of Leicester
Leicester
UK

Andrew W Bradbury
University Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham
UK

Edward Choke
Department of Vascular Surgery
University of Leicester
Leicester
UK

Gillian Cockerill
Department of Clinical Sciences
St George's Hospital Medical School
London
UK

Prue Cowled
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Helen Daly
Royal Perth Hospital
Perth, WA
Australia

Mital Desai
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Robert F Diegelmann
Department of Biochemistry
Medical College of Virginia
Richmond, VA
USA

Timothy K Fisher
Rashid Centre for Diabetes and Research
Sheikh Khalifa Hospital
Ajmon
UAE

Robert A Fitridge
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Gail Gillespie
Royal Perth Hospital
Perth, WA
Australia

Jonathan Golledge
Vascular Biology Unit
School of Medicine & Dentistry
James Cook University
Townsville, QLD
Australia

George Hamilton
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Mark Hamilton
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Robert J Hinchliffe
St George's Vascular Institute
St George's Hospital
London
UK

Richard D Kenagy
Department of Surgery
University of Washington
Seattle, WA
USA

Paul Kerr
Department of Pharmacology
University of Alberta
Alberta
Canada

Michael MD Lawrence-Brown
Curtin Health Innovation Research
Institute
Curtin University
Perth, WA
Australia

Brian Lepow
The University of Arizona
Department of Surgery
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Kurt Liffman
CSIRO Material Science & Engineering
and School of Mathematical Sciences
Monash University
Melbourne, Vic
Australia

Ian Loftus
Department of Vascular Surgery
St George's Hospital
London
UK

Mark J McCarthy
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Greg S McMahon
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Simon McRae
Adult Haemophilia Treatment Centre
SA Pathology
Adelaide, SA
Australia

Joseph L Mills
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Lyle Moldawer
Department of Surgery
University of Florida
Gainesville, FL
USA

John L Moran
Faculty of Health Sciences
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Stephen Nicholls
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Ian M Nordon
St George's Vascular Institute
St George's Hospital
London
UK

Paul E Norman
School of Surgery
University of WA
Fremantle, WA
Australia

Karlheinz Peter
Baker IDI Heart & Diabetes Institute
Melbourne, Vic
Australia

Frances Plane
Department of Pharmacology
University of Alberta
Alberta
Canada

Janet T Powell
Imperial College
London
UK

Sandeep Prabhu
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Rishi Puri
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Stephan A Schug
Royal Perth Hospital
Perth, WA
Australia

Gregory S Schultz
Department of Obstetrics and Gynaecology
University of Florida
Gainesville, FL
USA

Rahul Sharma
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Guo-Ping Shi
Department of Cardiovascular Medicine
Brigham & Women's Hospital
Harvard Medical School
Boston, MA
USA

Michael Stacey
University Department of Surgery
Fremantle Hospital
Fremantle, WA
Australia

Ilija D Sutalo
CSIRO Material Science & Engineering
and Curtin Health Innovation
Research Institute
Curtin University
Highett, Vic

Raymond Tam
Department of Pharmacology
University of Alberta
Alberta
Canada

Matthew Thompson
St Georges Hospital Medical School
London
UK

Martin Veller
Department of Surgery
University of Witwatersrand
Johannesburg
South Africa

Mauro Vicaretti
Department of Vascular Surgery
Westmead Hospital
Westmead, NSW
Australia

Matt Waltham
Academic Department of Surgery
St Thomas' Hospital
London
UK

Matthew L White
Vascular and Endovascular Surgery
University of Arizona
Tucson, AZ
USA

David P Wilson
School of Medical Sciences
Discipline of Physiology
University of Adelaide
Adelaide SA
Australia

Qingbo Xu
Department of Cardiology
Kings College
University of London
UK

Detailed Contents

CHAPTER 1 – ENDOTHELIUM

Paul Kerr, Raymond Tam, Frances Plane

- Introduction 1
- Endothelium-dependent regulation of vascular tone 2
- Angiogenesis 7
- Haemostasis 8
- Inflammation 9
- Conclusions 10
- References

CHAPTER 2 – VASCULAR SMOOTH MUSCLE STRUCTURE AND FUNCTION

David Wilson

- Introduction 13
- Smooth muscle (vascular) structure
- Cytoskeleton 14
- Contractile myofilament
- Functional regulation of vascular smooth muscle: Neuronal, hormonal, receptor mediated 15
- Smooth muscle function 17
- Myofilament basis of smooth muscle contraction and relaxation
- Smooth muscle contraction and relaxation 18
- Ion channels important in the regulation of smooth muscle function
- Regulation of cellular Ca^{2+}
- Sources of cytosolic Ca^{2+} entry 19
- Potassium channels
- Endothelial regulation of smooth muscle vasodilatation 20

Smooth muscle proliferation and vascular remodeling 20

Summary 22

References

CHAPTER 3 – ATHEROSCLEROSIS

Gillian Cockerill, Qingbo Xu

Introduction 25

Atherosclerotic lesions 26

Fatty streaks

Plaque or atheroma

Hypercholesterolemia and oxidised-LDL 27

High-density lipoproteins role in atheroprotection 28

Hypertension and biomechanical stress 29

Biomechanical stress-induced cell death 30

Biomechanical stress and inflammation 31

Biomechanical stress-induced smooth muscle cell proliferation 32

Infections and heat shock proteins

Infections

Heat shock proteins 33

Infections and HSP expression

Infections, sHSP and innate immunity 34

Immune responses 36

MHC class II antigens and T cells

Oxidised LDL as a candidate antigen

HSP60 as a candidate antigen 37

B2-glycoprotein Ib as a candidate antigen

Inflammation

C-reactive protein	38
CD40/CD40L	
Summary and perspectives	39
References	

CHAPTER 4 – MECHANISMS OF PLAQUE RUPTURE

Ian Loftus

Introduction	43
Evidence for the ‘plaque rupture theory’	44
Coronary circulation	
Cerebral circulation	
The role of individual components of the arterial wall	
The endothelium	45
The lipid core	47
The cap of the plaque	49
Smooth muscle cells and collagen production	50
Macrophages and collagen degradation	51
The vessel lumen	56
The role of angiogenesis in plaque rupture	
The role of infectious agents in plaque rupture	57
Risk prediction of plaque instability	58
Imaging	
Blood markers	59
Therapy aimed at plaque stabilisation	
HMG Co-A reductase inhibitors	60
MMP inhibition	
Tissue inhibitors of metalloproteinases (TIMPs)	61
Synthetic MMP inhibitors	
Doxycycline	
ACE inhibitors	
Summary	62
References	63

CHAPTER 5 – CURRENT AND EMERGING THERAPIES IN ATHEROPROTECTION

Stephen Nicholls, Rishi Puri

Background	79
Pathology	
Risk factor modification	80
Statins, LDL lowering and C-reactive protein	
The complexity of HDL	84
The controversy of triglycerides	87
Hypertension	
Risk factor modification in the diabetic patient	89
Glycaemic control	
Global risk factor reduction in diabetics	91
The metabolic syndrome	92
Future targets	93
Conclusion	
References	94

CHAPTER 6 – MOLECULAR APPROACHES TO REVASCULARISATION IN PERIPHERAL VASCULAR DISEASE

Greg S McMahon, Mark J McCarthy

Introduction	103
Mechanisms of vascular growth	
Vasculogenesis	
Angiogenesis	104
Neovessel maturation	105
Microvascular network maturation	106
Arteriogenesis	
Therapeutic induction of vascular growth	107
Delivery of molecular activators of vascular growth	
Angiogenic activators	108
Arteriogenic activators	109
Clinical trials for angiogenic therapy of peripheral vascular disease	
Conclusions	110
References	

CHAPTER 7 – BIOLOGY OF RESTENOSIS AND TARGETS FOR INTERVENTION

Richard Kenagy

Introduction 115

Mechanisms of restenosis

Thrombosis 116

Remodelling

Intimal hyperplasia 123

Sequence of events after injury

Origin of intimal cells 125

Inflammation 126

Role of ECM production 127

The contribution of specific factors to restenosis

Growth factors/cytokines

Inhibitors 128

Coagulation and fibrinolytic factors 129

Matrix metalloproteinases

Extracellular matrix/receptors

Targets for intervention 130

Intracellular signalling molecules

mTOR and microtubules

Transcription factors

miRNA 131

Inflammation targets

Brachytherapy

Extracellular targets and cell-based therapies

Angiotensin pathway

Cell-based therapies 132

Differential effects on endothelium and SMCs

Delivery devices

Prevention versus reversal of restenosis

Conclusions 133

References 134

CHAPTER 8 – VASCULAR ARTERIAL HAEMODYNAMICS

Michael Lawrence Brown, Kurt Liffman, James Semmens, Ilija Sutalo

Introduction 153

Laplace's law of wall of tension 154

Newtonian fluid 155

Non-Newtonian fluid

Poiseuille flow 158

Bernoulli's equation

Young's modulus and pulsatile flow 159

Mass conversion 161

Reynold's number

Arterial dissection, collateral circulation and competing flows 163

Shear stress and pressure 164

Forces on graft systems 165

Case 1 – The cylindrical graft 168

Case 2 – The windsock graft

Case 3 – The curved graft 169

Case 4 – The symmetric bifurcated graft

Computational modelling 170

Recent development and future directions 171

Conclusions 172

References 173

CHAPTER 9 – PHYSIOLOGICAL HAEMOSTASIS

Simon McRae

Introduction 177

Primary haemostasis

Platelets

Platelet adhesion

Platelet activation and shape change 179

Platelet aggregation 180

Interactions between primary and secondary haemostasis 181

Secondary haemostasis

The coagulation cascade 182

Initiation 183

Amplification

Propagation 184

Normal inhibitors of coagulation

Fibrinolysis 185

Conclusions 186

References

CHAPTER 10 – HYPERCOAGULABLE STATES

Simon McRae

Introduction 189

Classification of thrombophilia

Inherited thrombophilia 190

Type 1 conditions

Antithrombin deficiency

Protein C and Protein S deficiency

Type 2 conditions 191

Factor V Leiden

The prothrombin (G20210A) gene mutation

FVL/PGM compound heterozygotes

Other inherited conditions

Acquired thrombophilia 192

Antiphospholipid antibodies

Heparin induced thrombocytopenia

Myeloproliferative disorders 193

Potential reasons for performing thrombophilia testing

Patients with venous thrombosis and their relatives

Providing an understanding of the aetiology of a thrombotic event

Determining risk of recurrence and therefore optimal duration of anticoagulation 194

Determining the need for primary prophylaxis in asymptomatic family members 195

Making decisions regarding the use of the oral contraceptive pill 196

Determining the need for thromboprophylaxis during pregnancy

Patients with arterial thrombosis

Potential detrimental effects of thrombophilia testing 197

Conclusion

References

CHAPTER 11 – PLATELETS IN THE PATHOGENESIS OF

VASCULAR DISEASE AND THEIR ROLE AS A THERAPEUTIC TARGET

*Sandeep Prabhu, Rahul Sharma,
Karlheinz Peter*

Introduction 201

Platelet function – Adhesion and activation

Platelet adhesion 202

Platelet activation 203

Mediators of platelet activation and ‘outside in’ signalling

Thrombin and collagen 204

Adenosine diphosphate (ADP)

Thromboxane A2 (TXA2)

Adrenaline 206

Second messenger systems 207

Physiological consequences of platelet activation

The GP IIb/IIIa receptor and ‘inside-out’ signalling

Granule exocytosis 208

Activation-induced conformational change of platelets

Platelets and atherosclerosis 209

Role of platelets in the initiation of the atherosclerosis

Role of the platelets in the progression of the atherosclerosis

Role of platelets in vulnerable plaques and plaque rupture

Current and future anti-platelet agents 210

Aspirin (salicylic acid)

Thienopyridines 211

Clopidogrel

Prasugrel 213

Ticlopidine

Ticagrelor

GPIIb/IIIa Antagonists

Other anti-platelet agents and promising new developments 214

Platelet function testing 215

Light-transmission aggregometry

Whole blood aggregometry 217
 VerifyNow® Assay
 Flow cytometry 218

References

CHAPTER 12 – PATHOGENESIS OF AORTIC ANEURYSMS

*Jonathan Golledge, Guo-Ping Shi,
 Paul E Norman*

Introduction 227

Differences between thoracic and abdominal aortic aneurysms 228

Summary of current theories and stages of AAA evolution

Atherosclerosis and AAA

Immune mechanisms in AAA 229

Extracellular matrix dysfunction 232

Infection 233

Biomechanical forces

Angiogenesis

Intra-luminal thrombus

Extracellular matrix proteolysis 234

Genetics 236

AAA rupture 237

Biomechanical factors in aneurysms rupture

The role of enzymes in AAA rupture

Role of intraluminal thrombus in aneurysm rupture 238

Future research

References

CHAPTER 13 – PHARMACOLOGICAL TREATMENT OF ANEURYSMS

Matthew Thompson, Janet T Powell

Background 247

Screening programmes

Pathophysiology 248

Therapeutic strategies

Beta blockade

Modification of the inflammatory

response 249

Non-steroidal anti-inflammatories

Matrix metalloproteinase (MMP)

inhibition

Anti-chlamydial therapy 250

Drugs acting on the renin/angiotensin axis

HMG Co-A reductase inhibitors 251

The future – Data from recent

experimental studies

References

CHAPTER 14 – PATHOPHYSIOLOGY OF AORTIC DISSECTION AND CONNECTIVE TISSUE DISORDERS

Mark Hamilton

Introduction 255

Embryology of thoracic aorta and arch vessels

Haemodynamics of thoracic compared to abdominal aorta 257

Sizes of normal aorta

Classification of aortic syndromes

Acute/Chronic

DeBakey classification of class 1 dissection – Type 1, 2, and 3

Stanford classification 258

European task force

Pathogenesis of thoracic aortic dissection

Classical thoracic aortic dissection (class 1 dissection) 260

Intramural haematoma (class 2 aortic dissection) 261

Penetrating aortic ulcer (class 4 aortic dissection) 262

Complications of acute aortic syndromes 263

Visceral ischaemia /malperfusion syndromes

Fate of the false lumen

Aneurysmal degeneration and rupture 264

Connective tissue disorders and acute aortic syndromes

Marfan syndrome	
Fibrillin and Marfan syndrome	265
The role of transforming growth factor beta in development of the vascular system in health and disease	266
Ehlers-Danlos syndrome	267
Diagnosis of Ehlers-Danlos syndrome	268
Loeys-Deitz syndrome	270
Familial thoracic aortic aneurysm disease	271
Bicuspid aortic valve	273
Turners Syndrome	
Summary	274
Reference list	

CHAPTER 15 – BIOMARKERS IN VASCULAR DISEASE

Ian M Nordon, Robert J Hinchliffe

Introduction	277
What is a biomarker?	
Types of biomarkers	
A classical clinical example	278
Potential value of biomarkers in vascular disease	279
Biomarker discovery steps	280
AAA biomarkers	
Circulating extracellular matrix markers	281
Matrix-degrading enzymes	283
Proteins associated with thrombosis	
Markers of inflammation	284
Biomarkers of AAA rupture	285
Biomarkers following endovascular repair	
Inflammation	287
Lipid accumulation	
Apoptosis	
Thrombosis	
Proteolysis	288
Challenges in biomarkers discovery	
Future work	
Conclusion	289
References	

CHAPTER 16 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VASCULITIS AND RAYNAUD'S PHENOMENON

Martin Veller

Vasculitides	295
Introduction	
Classification of vasculitides	296
Clinical presentation of vasculitides	
Investigations of vasculitides	
Principles of treatment of vasculitides	297
The vasculitides of specific interest to vascular surgeons	298
Giant cell arteritis	
Takayasu's arteritis	299
Thromboangitis obliterans (Buerger's disease)	300
Behcet's disease	301
Polyarteritis nodosa	302
Vasculitides secondary to connective tissue diseases	303
Systemic lupus erythematosus (SLE)	
Antiphospholipid antibody syndrome (APS)	304
Rheumatoid arthritis	305
Scleroderma	
Infective vasculitides	306
Human immunodeficiency virus (HIV)	
Pathophysiology and principles of Raynaud's phenomenon	307
Prevalence of Raynaud's phenomenon	308
Clinical findings in Raynaud's phenomenon	309
Diagnosis of Raynaud's phenomenon	
Prognosis	310
Treatment	
Recommendations	311
References	312

CHAPTER 17 – SIRS, SEPSIS AND

MULTIORGAN FAILURE*Vishwanath Biradar, John Moran***Epidemiology 315****Historical perspectives and definition 316****Risk factors for sepsis 317**

Causative agents

Pathophysiology of sepsis

innate immunity and toll-like receptors (TLRs) 319

Proinflammatory response

Coagulation cascade

Multorgan dysfunction syndrome (MODS) 320

Epithelial and endothelial dysfunction

Immune suppression and apoptosis

Sepsis, circulatory failure and organ dysfunction

Management 322

Steroids 323

Recombinant human activated protein C (rhAPC) 324

Glucose control 325

Renal replacement therapy

3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors (HMG-CoA) 326

Other adjuvant therapies in sepsis

Cytokines and anticytokine therapies

Pooled immunoglobulin (IVIG)

Acute respiratory distress syndrome (ARDS) 327

References**CHAPTER 18 –
PATHOPHYSIOLOGY OF
REPERFUSION INJURY***Prue Cowled, Rob Fitridge***Introduction 331****Ischaemia**

ATP and mitochondrial function

Gene expression during ischaemia 332

Reperfusion 333

Reactive oxygen species

Eicosanoids 334

Nitric Oxide 335

Endothelin 336

Cytokines

Neutrophil and endothelial interactions 338

Complement activation 340

Tissue destruction 341

Proteases and metalloproteinases

Apoptotic cell death during ischaemia-reperfusion injury

No-reflow phenomenon 342

Therapeutic approaches to IRI

Ischaemic preconditioning

Ischaemic post-conditioning 343

Conditioning effects of volatile anaesthetics

Pharmacological treatments 344

Summary 345**References****CHAPTER 19 – COMPARTMENT
SYNDROME***Edward Choke, Robert Sayers, Matthew Bown***Definition 351****Acute limb compartment syndrome**

Incidence

Anatomy/physiology 352

Aetiology/pathophysiology

Clinical presentation 354

Investigation 355

Treatment 357

Complication of LCS 359

Outcome 360

Acute abdominal compartment syndrome

Incidence 361

Aetiology

Pathological effects of raised intra-abdominal pressure 362

Clinical presentation 363

Investigation

Treatment 364

Complications of surgical decompression

Outcome 367

References 368

CHAPTER 20 – PATHOPHYSIOLOGY OF PAIN

Stephan Schug, Helen Daly, Kathryn Stannard

Introduction 375

Peripheral mechanisms

Nociception/transduction

Conduction 376

Spinal cord mechanisms

Ascending systems 377

Descending control

Pain modulation 378

Peripheral sensation

Central sensitisation in the dorsal horn

Neuropathic pain 379

Mechanisms of neuropathic pain

Peripheral mechanisms

Spontaneous ectopic discharge

Altered gene expression

Spared sensory neurons

Involvement of the sympathetic nervous system 380

Collateral sprouting

Effects of bradykinin

Central mechanisms

Wind up

Central sensitization 381

Central disinhibition

Expansion in receptive field size (recruitment)

Immediate early gene expression

Anatomical re-organisation of the spinal cord

Contribution of glial cells to pain conditions 382

Symptoms of neuropathic pain

Stimulus-dependent pain

Stimulus-independent pain 383

Sympathetically maintained pain (SMP)

Neuropathic pain syndromes

Peripheral neuropathies

Central neuropathies 385

References

CHAPTER 21 – POST-AMPUTATION PAIN

Stephan Schug, Gail Gillespie

Introduction 389

Classification and incidence of post-amputation pain syndromes

Stump pain

Phantom sensation 390

Phantom limb pain

Pathophysiology of post-amputation pain syndromes

Peripheral factors

Spinal factors 391

Supraspinal factors

Current pathophysiological model of post-amputation pain syndromes 392

Prevention of post-amputation pain

Perioperative lumbar epidural blockade

Peripheral nerve blockade 393

NMDA antagonists

Evaluation of the patient with post-amputation pain syndromes

Examination

Therapy of post-amputation pain syndromes 394

Calcitonin

Ketamine

Analgesic and Co-analgesic compounds

Opioids 395

Gabapentin

Clonazepam

Lidocaine

Carbamazepine

Tricyclic antidepressants (TCA)

Selective serotonin reuptake inhibitors

Baclofen

Capsaicin

Symptomatic treatment of pain components 396

Neuropharmacological therapies

Invasive therapies
 Electroconvulsive therapy (ECT)
 Nerve blockade
 Spinal cord stimulation
 Implantable intrathecal delivery systems
 Dorsal root entry zone (DREZ) lesions
 Psychological therapy 397

Future aims

References

CHAPTER 22 – TREATMENT OF NEUROPATHIC PAIN

Stephan Schug, Kathryn Stannard

Introduction 401

Principles of treatment

Pharmacological treatment 402

Opioids

Recommendations for clinical use of opioids

Tramadol

Mechanism of action

Efficacy 403

Adverse effects

Recommendations for clinical use of tramadol in neuropathic pain

Antidepressants

Tricyclic antidepressants (TCAs)

Mechanism of action 404

Adverse effects

Selective serotonin re-uptake inhibitors (SSRIs)

Serotonin/Noradrenaline reuptake inhibitors (SNRIs) 405

Recommendations for clinical use of antidepressants as analgesics

Anticonvulsants

Mechanism of action 406

Individual medications

Clonazepam

Gabapentin

Pregabalin 407

Carbamazepine

Sodium valproate 408

Phenytoin

Lamotrigene

Recommendations for clinical use of anticonvulsants as analgesics

Local anaesthetics and antiarrhythmics 409

Mechanism of action

Lignocaine

Mexiletine

Recommendations for clinical use of lignocaine and mexiletine in neuropathic pain

N-methyl-D-aspartate-receptor antagonists (NMDA)

Ketamine 410

Other NMDA antagonists

Miscellaneous compounds for systemic use

Clonidine

Efficacy

Baclofen

Levodopa 411

Cannabinoids

Topical treatments

Lignocaine 5% medicated plaster

Capsaicin 412

Mechanism of action

Efficacy

Non-pharmacological therapy

Transcutaneous electrical nerve stimulation (TENS)

Spinal cord stimulation (SCS) 413

Sympathetic nerve blocks

Neurosurgical destructive techniques

Cognitive behaviour therapy

References 414

CHAPTER 23 – PRINCIPLES OF WOUND HEALING

Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann

Introduction 423

Phases of acute wound healing

Haemostasis

- Inflammation 426
 - Neutrophils 427
 - Macrophages 428
- Proliferative phase 429
 - Fibroblast migration 430
 - Collagen and extracellular matrix production
 - Angiogenesis 431
 - Granulation 432
 - Epithelialization
 - Remodelling 433
- Summary of acute wound healing 435
- Comparison of acute and chronic wounds**
 - Normal and pathological responses to injury
 - Biochemical differences in the molecular environments of healing and chronic wounds 436
 - Biological differences in the response of chronic wound cells to growth factors 439
- From bench to bedside**
 - Role of endocrine hormones in the regulation of wound healing
 - Molecular basis of chronic non-healing wounds
 - Chronic venous stasis ulcers 441
 - Pressure ulcers
- Future concepts for the treatment of chronic wounds 442**
 - Bacterial biofilms in chronic wounds 443
- Conclusion 445**
- References**

CHAPTER 24 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VARICOSE VEINS

Andrew Bradbury

- Introduction 451**
- Anatomy**
- Histology 452**
- Physiology**

- Varicose veins 453**
- Valvular abnormalities**
- Muscle pump failure 455**
- Venous recirculation**
- Recurrent varicose veins**
 - New varicose veins
 - Persistent varicose veins
 - True recurrent varicose veins 456
- Cellular and molecular biology of varicose veins**
- Conclusion 457**
- References**

CHAPTER 25 – CHRONIC VENOUS INSUFFICIENCY AND LEG ULCERATION: PRINCIPLES AND VASCULAR BIOLOGY

Michael Stacey

- Definitions 459**
 - Chronic venous insufficiency
 - Leg ulceration
 - Assessment of cause of leg ulceration 460
- Epidemiology 461
- Pathophysiology
 - Venous abnormality
 - Effect of ambulatory venous hypertension on the tissues in the leg 463
 - Influence of venous disease on the wound healing process 465
 - Genetic associations with venous ulceration 466
- Assessment of venous function 467**
- Treatment of venous ulceration**
 - Compression therapy
 - Dressings 468
 - Surgery
 - Prevention of venous ulcer recurrence 470
 - Sclerotherapy and other techniques to obliterate surface and perforating veins
 - Other therapies 471
- References**

CHAPTER 26 –
PATHOPHYSIOLOGY AND
PRINCIPLES OF MANAGEMENT
OF THE DIABETIC FOOT

*David Armstrong, Timothy Fisher, Brian
Lepow, Matthew White, Joseph Mills*

- Introduction** 475
- Pathophysiology of the diabetic foot** 476
- Neuropathy
 - Structural abnormalities/gait abnormalities
 - Angiopathy 478
- Diagnosis**
- History and rapid visual screening
 - Neurological examination 479
 - Monofilament testing
 - Vibration testing
 - Dermatologic examination 480
 - Anatomy of occlusive disease – vascular examination
 - Prediction of wound healing: assessment of perfusion 481
 - Arterial imaging
 - Soft tissue imaging 482
- Classification systems** 483
- Diabetes mellitus foot risk classification
 - University of Texas wound classification system
- Clinical problems and principles of management** 484
- Ulceration
 - Epidemiology and risk factors
 - Offloading
 - Non-vascular surgical treatment 485
 - Class I – Elective 486
 - Class II – Prophylactic
 - Class III – Curative
 - Class IV – Emergency (urgent)
 - Post-operative management
 - Infections 487
 - Charcot arthropathy
- Prevention** 490
- Conclusion** 492
- References**

CHAPTER 27 – LYMPHOEDEMA
– PRINCIPLES, GENETICS AND
PATHOPHYSIOLOGY

Matt Waltham

- Introduction** 497
- Classification of lymphoedema**
- Classification of primary lymphoedema 498
- The genetics of lymphangiogenesis in primary lymphoedema** 500
- Milroy's disease
 - Lymphoedema – distichiasis syndrome 501
 - Hypotrichosis – lymphoedema – telangiectasia syndrome 502
 - Meige disease (primary non-syndromic lymphoedema)
 - Other primary lymphoedema disorders 503
- Structure and development of the lymphatic circulation**
- Clinical aspects of lymphoedema** 505
- Summary**
- References**

CHAPTER 28 – GRAFT
MATERIALS PAST AND FUTURE

Mital Desai, George Hamilton

- The pathophysiology of graft healing** 511
- The peri-anastomotic area
 - Healing of prosthetic grafts 512
 - The healing process of the anastomosis
 - Graft porosity and permeability
- Physical properties of prosthetic materials** 514
- Tubular compliance
 - Anastomotic compliance mismatch
 - The compliance hypothesis of graft failure
- Synthetic grafts** 515
- Newer developments of Dacron grafts
 - Modifications and newer developments of PTFE grafts 517
 - Polyurethane grafts

Newer developments of polyurethane vascular grafts	518
Biological vascular grafts	519
Newer developments of biological vascular grafts	520
Prosthetic graft modifications	
Modifications to reduce graft infection	
Modifications to improve patency	521
Nanocomposite grafts	
Endothelial cell seeding	522
Single stage seeding	
Two stage seeding	
Vascular tissue engineering	
Non-degradable polymer and cell seeding	523
Bioresorbable and biodegradable polymers	
Combined bioresorbable and tissue engineered grafts	524
Mechanical conditioning of seeded vascular cells	
Alternative scaffolds	
Tissue-engineered grafts	525
Graft materials for aortic endografts	526
The future	
References	527

CHAPTER 29 – PATHOPHYSIOLOGY OF VASCULAR GRAFT INFECTIONS

Mauro Vicaretti

Introduction	537
Natural history of prosthetic vascular graft infections	
Mechanism of graft contamination at operation	538
Pathogenesis of graft infections	
Bacteriology of vascular graft infections	
Investigations for detection of prosthetic graft infections	539
History and physical examination	
Laboratory investigations	
Diagnostic imaging	540
Management of prosthetic graft infections	
Prevention	
Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron	541
Established infection	
Antibiotic therapy	
Operative management	
Conclusion	542
References	

Acknowledgements

The Editors gratefully acknowledge the outstanding contributions of each Author involved in this reference book. We would also like to acknowledge the invaluable efforts of Ms Sheona Page who has worked tirelessly on this project. We would also like to thank Prue Cowled PhD and Ms Cayley Wright for their assistance.

Abbreviation List

a1-PI	a1-protease inhibitor
5-HT	5-Hydroxytryptamine/Serotonin
AAA	Abdominal aortic aneurysm
AAS	Acute aortic syndrome
AAV	Adeno-associated viruses
ACE	Angiotensin converting enzyme
ACS	Acute coronary syndrome
ACS	Abdominal compartment syndrome
ACTH	Adrenocorticotrophic hormone
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ADP	Adenosine diphosphate
AIDS	Acquired immune deficiency syndrome
ALI	Acute lung injury
AMP	Adenosine monophosphate
AMPA	α -amino-3 hydroxy-5-methylisoxazole
ANA	Anti-nuclear antibody
ANCA	Anti-neutrophil cytoplasmic antibody
AOD	Aortic occlusive disease
AP1	Activated protein 1
APC	Activated protein C
APC	Antigen presenting cell
APLAS	Antiphospholipid antibody syndrome
ApoAI	Apolipoprotein AI
ApoE	Apolipoprotein E
APS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time

ARDS	Acute respiratory distress syndrome
AT	Antithrombin
ATP	Adenosine triphosphate
AVP	Ambulatory venous thrombosis
β 2-GPI	β 2-glycoprotein Ib
bFGF	Basic fibroblast growth factor
BKCa	Large conductance calcium activated potassium channel
BMPs	Bone morphogenetic proteins
BMS	Bare metal stent
CAD	Coronary artery disease
CaM	Calmodulin
CAM	Cell adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCK	Cholecystokinin
cGMP	Cyclic guanine monophosphate
CD	Cluster of differentiation
CD40L	Cluster of differentiation 40 ligand
CEA	Carotid endarterectomy
CETP	Cholesteryl ester transfer protein
CFD	Computational fluid dynamics
CG	Cationized gelatin
CGRP	Calcitonin gene regulated peptide
CHD	Coronary heart disease
CI	Confidence interval
CIMT	Carotid intimal-media thickness
c-JNK	c-Jun N-terminal kinase
CK-MB	Creatinine kinase (Myocardial specific)
CNCP	Chronic noncancer pain
cNOS	Constitutive nitric oxygen synthase enzyme
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CROW	Charcot restraint orthotic walker
CRRT	Continuous renal replacement therapy

CRP	C-reactive protein
CRPS	Complex regional pain syndromes
CT	Computational tomography
CTA	Computed tomographic angiography
CTD	Connective tissue disorders
CTGF	Connective tissue growth factor
CYP	Cytochrome P450
CVD	Cardiovascular disease
CVI	Chronic venous insufficiency
DAG	Diacylglycerol
DES	Drug-eluting stent
DRG	Dorsal root ganglion
DNA	Deoxyribonucleic acid
DSA	Digital subtraction arteriography
DTS	Dense tubular system
DVT	Deep vein thrombosis
EC	Endothelial cell
ECM	Extracellular matrix
EDCF	Endothelium-derived contracting factor
EDH	Endothelium-dependent hyperpolarisation
EDS	Ehlers-Danlos syndrome
EET	Epoxyeicosatrienoic acids
ELAM-1	Endothelial-leukocyte adhesion molecule-1
ELG	Endoluminal grafts
ELISA	Enzyme linked immunosorbent assay
E_K	Equilibrium potential
E_M	Membrane potential
eNOS	Endothelial nitric oxide synthase enzyme
EPC	Endothelial progenitor cells
EPCR	Endothelial protein C receptor
ePTFE	Expanded polytetrafluoroethylene
ERK	Extracellular signal-regulated kinase
ESR	Erythrocyte sedimentation rate

ET	Essential thrombocytosis
ET-1	Endothelin 1
EVAR	Endovascular aortic aneurysm repair
EVLA	Endovenous LASER ablation
FDA	Food and drug administration
FDPs	Fibrin degradation products (soluble)
FGF	Fibroblast growth factor
FGF-2	Fibroblast growth factor 2
FMN	Flavin mononucleotide
FVL	Factor V Leiden
GABA	Gamma-aminobutyric acid
GABA B	Gamma-aminobutyric acid subtype B
G-CSF	Granulocyte colony stimulating factor
GMCSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GPCR	G-protein coupled receptor
GSV	Great saphenous vein
HDL	High density lipoprotein
HDL-C	High density lipoprotein cholesterol
HIF	Hypoxia inducible factor
HIT	Heparin induced thrombocytopenia
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMG Co-A	Hydroxymethylglutaryl coenzyme-A
HMW	High molecular weight
HPETE	Hydroperoxyeicosatetraenoic acid
HETE	Hydroxyeicosatetraenoic acids
HR	Hazard ratio
hsCRP	High-sensitive C-reactive protein
HSP	Heat shock protein
HUV	Human umbilical vein
IAH	Intra-abdominal hypertension

IAP	Intra-abdominal pressure
IAPP	Intra-abdominal perfusion pressure
ICAM-1	Inter-cellular adhesion molecule-1
ICAM-2	Inter-cellular adhesion molecule-2
ICP	Intra-compartmental pressure
ICU	Intensive care unit
IFN	Interferon
IGF-1	Insulin-like growth factor-1
IHD	Ischemic heart disease
IL	Interleukin
IL-1	Interleukin-1
IL-1 α	Interleukin-1 alpha
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
ILT	Intraluminal thrombus
IKCa	Intermediate conductance calcium-activated potassium channels
IMH	Intramural haematoma
IMP	Inosine monophosphate
iNOS	Inducible nitric oxide synthase enzyme
IP(3)	1,4,5-inositol triphosphate
IRI	Ischemia reperfusion injury
IVIG	Intravenous pooled immunoglobulin
IVUS	Intravascular ultrasound
KGF	Keratinocyte growth factor
KGF-2	Keratinocyte growth factor-2
LAP	Latency associated peptide
LCS	Limb compartment syndrome
LDL	Low density lipoprotein
LDS	Loeys-Dietz syndrome
LLC	Large latent complex
LEC	Lymphatic endothelial cells

LFA-1	Lymphocyte function-associated antigen-1
LO	Lipoxygenase
LOX	Lysyl oxidase
LOPS	Loss of protective sensation
LPA	Lysophosphatidic acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
LTGFBP	Latent TGF binding protein
MAC-1	Macrophage-1 antigen
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MFS	Marfan syndrome
MHC	Major histocompatibility
MI	Myocardial infarction
MIP-1	Macrophage inflammatory protein-1
MLC ₂₀	Myosin light chain ₂₀
MLCK	Myosin light chain kinase
MLCP	Myosin light chain phosphatase
MMP	Matrix metalloproteinase
MODS	Multiple organ dysfunction syndrome
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin resistant <i>Staphylococcus epidermidis</i>
MRTA	Magnetic resonance tomographic angiography
MTHFR	Methylenetetrahydrofolate reductase
MT-MMP	Membrane-type MMP
MVPS	Mitral valve prolapse syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NGF	Nerve growth factor

NFκB	Nuclear factor kappa B
NiTi	Nitinol
NJP	Non-junctional perforators
NMDA	N-methyl-D-aspartate
NNH	Number needed to harm
NNT	Number needed to treat
NO	Nitric oxide
NOS	Nitric oxide synthase enzyme
NSAID	Non-steroidal anti-inflammatory drug
NV	Neovascularisation
OCP	Oestrogen/progesterone contraceptive pill
OPN	Osteopontin
OPG	Osteoprotegerin
OR	Odds ratio
OxLDL	Oxidised low density lipoprotein
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAI	Plasminogen activator inhibitor
PAI-1	Plasminogen activator inhibitor-1
PAR	Protease activated receptor
PAR-1	Protease activated receptor-1
PAR-4	Protease activated receptor-4
PAU	Penetrating aortic ulcer
PC	Protein C
PCA	Poly (carbonate-urea) urethane
PCI	Percutaneous coronary intervention (angioplasty)
PCWP	Pulmonary capillary wedge pressure
PDGF	Platelet-derived growth factor
PDGFβ	Platelet-derived growth factor-β
PDS	Polydioxanone
PECAM-1	Platelet-endothelial cell adhesion molecule-1
PEDF	Pigment epithelium-derived factor
PES	Paclitaxel-eluting stent

PET	Positron emission tomography
PF4	Platelet factor 4
PGI ₂	Prostacyclin
PGG ₂	Prostaglandin G ₂
PGH ₂	Prostaglandin H ₂
PGEI ₂ /PGI ₂	Prostaglandin I ₂
PGN	Peptidoglycan
PHN	Postherpetic neuropathy
PHZ	Para-anastomotic hyper-compliant zone
PI3K	Phosphatidylinositol 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PLOD	Procollagen lysyl hydroxylase
PMCA	Plasma membrane Ca ²⁺ APTases
PMN	Polymorphonuclear leukocyte
POSS	Polyhedral oligomeric silsesquioxanes
PPAR	Peroxisomal proliferation activating receptor
PPI	Proton pump inhibitor
PRV	Polycythaemia rubra vera
PS	Protein S
PSGL-1	P-selectin glycoprotein ligand-1
PT	Prothombin time
PTCA	Percutaneous coronary angioplasty
PTFE	Polytetrafluoroethylene
PTS	Post-thrombotic syndrome
PUFA	Polyunsaturated fatty acid
PVI	Primary valvular incompetence
rAAA	Ruptured AAA
Rac	Ras activated cell adhesion molecule
RANTES	Regulated upon activation, normal T cell expressed and secreted
RAS	Renin angiotensin system
RCT	Randomised controlled trial

RF	Rheumatoid factor
RFA	Radiofrequency ablation
rhAPC	Recombinant human activated protein C
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RR	Relative risk
RSD	Reflex sympathetic dystrophy
S1P	Sphingosine-1-phosphate
SAPK	Stress-activated protein kinase
SCF	Stem cell factor
SCS	Spinal cord stimulation
ScvO2	Superior vena cava venous oxygen saturation
SDF-1	Stromal-cell-derived factor-1
SERCA	Sarco/endoplasmic reticulum CaATPases
SEP	Serum elastin peptides
SES	Sirolimus-eluting stent
SEPS	Subfascial endoscopic perforator surgery
SFA	Superficial femoral artery
SFJ	Sapheno-femoral junction
SIRS	Systemic inflammatory response syndrome
SKCa	Small conductance calcium-activated potassium channels
SLE	Systemic lupus erythematosus
SMA	Smooth muscle alpha actin
SMC	Smooth muscle cell
SMP	Sympathetically maintained pain
SNARE	Soluble N-ethylmaleimide-sensitive factor activating protein receptors
SNP	Single nucleotide polymorphisms
SNRI	Serotonin/Noradrenaline reuptake inhibitors
SPJ	Sapheno-popliteal junction
SPP	Skin perfusion pressure
SR	Sarcoplasmic reticulum
SSRIs	Selective serotonin re-uptake inhibitors
SSV	Small saphenous vein

SVT	Superficial thrombophlebitis
STIM1	Stromal interacting molecule 1
T α CE	TNF α converting enzyme
TAAD	Thoracic aortic aneurysm disease
TAD	Thoracic aortic dissection
TAFI	Thrombin-activatable fibrinolysis inhibitor
Tc-99 MDP	Technetium-99 methylene diphosphonate
TCA	Tricyclic antidepressant
TCC	Total contact cast
TCR	T-cell receptor
TENS	Transcutaneous electrical nerve stimulation
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TGF	Transforming growth factor
TGF- α	Transforming growth factor-alpha
TGF- β	Transforming growth factor-beta
TGL	Triglycerides
Th	T helper
TIA	Transient ischemic attack
TIMP	Tissue inhibitors of metalloproteinase
TLR	Toll-like receptors
TNF	Tumour necrosis factor
TNF- α	Tumour necrosis factor-alpha
tPA	Tissue-type plasminogen activator
TRP	Transient receptor potential
TRPC	Transmembrane receptor potential canonical
TRPV1	Transmembrane receptor potential Vanilloid-type
TXA2	Thromboxane A2
uPA	Urokinase
UT	University of Texas
VCAM	Vascular cell adhesion molecule
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor

VEGF-R	Vascular endothelial growth factor receptor
VIP	Vasoactive intestinal peptide
VLA-1	Very late activating antigen-1
VOCC	Voltage operated calcium channels
VPT	Vibratory perception threshold
VSMC	Vascular smooth muscle cells
VTE	Venous thromboembolism
VV	Varicose veins
vWF	von Willebrand factor
XO	Xanthine oxidase

16 • Pathophysiology and Principles of Management of Vasculitides and Raynaud's Syndrome

MARTIN VELLER

VASCULITIDES

Occlusive arterial lesions in humans are usually caused by atherosclerosis. The primary and secondary vasculitides are rare inflammatory conditions that may also cause such ischaemia as well as occasional aneurysms. These pathologies usually present with unusual manifestations of ischaemia, but may also be the cause of common symptoms such as stroke, hypertension, intermittent claudication or Raynaud's phenomenon. Delayed recognition of these diseases is often associated with severe and irreversible complications. While the vasculitides are usually managed by physicians, vascular surgeons should be able to recognise them and assist in their management when appropriate.

INTRODUCTION

The vasculitides consist of primary and secondary pathologies in which non-specific transmural inflammation occurs within a blood vessel. The consequent vascular injury can cause vessel disruption, aneurysm formation or occlusion which can affect any blood vessel. The pathogenesis of each of these diseases is unclear, although they generally fall into one of the following groups:¹

- Immune complex vasculitides: These are induced by circulating immune complexes or histamine. This results in the activation of the complement system, cytokines and monocytes in the vessel wall.
- Pauci-immune vasculitides: The anti-neutrophil cytoplasmic antibodies (ANCA) were first described in conjunction with rapidly progressing glomerulonephritis. Cytoplasmic ANCA (c-ANCA), perinuclear ANCA (p-ANCA) and x-ANCA (which is found in chronic inflammatory GIT pathologies) have been described. In the pauci-immune vasculitides, activation of neutrophils results in vascular endothelial damage.²
- T-cell vasculitides: In these, vessel wall damage is caused by CD4 lymphocyte mediated immune reactions.

The primary vasculitides occur rarely – between 20 and 100 cases per million. They usually present with non-specific clinical symptoms and signs – e.g. malaise, fever, weight loss – and generally evolve over a long duration. In addition, they may overlap with the manifestations of much more common infections, connective tissue diseases and malignancy. As a consequence making the

diagnosis is challenging and is confounded by the extensive overlap in the clinical and pathological manifestations between the vasculitides.

If unrecognised, these systemic diseases may be fatal. With appropriate treatment the majority of patients will improve but relapses are common. These relapses may be the result of recurrence, worsening of the inflammatory process or may be the consequence of complications of therapy.

CLASSIFICATION OF VASCULITIDES

The heterogeneous nature and extensive overlapping clinical and pathological features have made classification difficult. Currently, the most commonly used systems take into account the size of the vessel affected, the histological findings and the aetiology (Table 16.1).^{1,3-5} There is also some value in differentiating between ANCA positive (e.g. Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss vasculitis, drug induced vasculitis) and ANCA negative vasculitides.¹

Whilst, the classification systems attempt to highlight the differences among these diseases, in clinical practice these differences are not precise – polyarteritis nodosa for example normally considered to be a primary, medium vessel vasculitis, can also be caused by chronic hepatitis B or C infections and may involve small vessels.^{1,5}

CLINICAL PRESENTATION OF VASCULITIDES

In general, vasculitis should be considered to be present when chronic systemic symptoms of inflammation, including pyrexia, malaise, fatigue, and weight loss are associated with some form of organ dysfunction. Arthralgia, myalgia, pain in the digits, rashes, anaemia

Table 16.1: The major vasculitides^{3,22}

<p>Primary vasculitis</p> <ul style="list-style-type: none"> Predominantly large vessel vasculitis <ul style="list-style-type: none"> Giant cell arteritis (also temporal arteritis) Takayasu's arteritis Predominantly medium vessel vasculitis <ul style="list-style-type: none"> Polyarteritis nodosa Kawasaki's disease Predominantly small vessel vasculitis <ul style="list-style-type: none"> Churg-Strauss syndrome Wegener's granulomatosis Microscopic polyangiitis Henoch-Schönlein purpura Essential cryoglobulinaemic vasculitis Hypersensitivity vasculitis No predominant vessel size <ul style="list-style-type: none"> Behçet's disease
<p>Secondary vasculitis</p> <ul style="list-style-type: none"> Vasculitis secondary to connective tissue disorders <ul style="list-style-type: none"> Rheumatoid vasculitis Systemic lupus erythematosus (SLE) Systemic sclerosis Scleroderma (including the CREST syndrome) Mixed connective tissue disease Antiphospholipid antibody syndromes Vasculitis secondary to viral disease <ul style="list-style-type: none"> Hepatitis B and C virus Human immunodeficiency virus (HIV) Cytomegalovirus Epstein-Barr virus Drug induced vasculitis
<p>Other vasculitides</p> <ul style="list-style-type: none"> Thromboangitis obliterans (Buerger's disease) Purpura fulminans (Waterhouse-Friderichsen) Thrombotic thrombocytopenic purpura

of chronic disorders, pericarditis and a raised ESR and CRP are also common. The common organ specific manifestations are listed in Table 16.2.

In general, the skin and peripheral nervous system signs are particularly useful because they tend to develop early in the course of

TABLE 16.2: The common clinical manifestations of the vasculitides

Skin	Livedo reticularis, palpable purpura, nodules, ulcers, gangrene
Peripheral nervous system	Mononeuritis multiplex, polyneuropathy
Central nervous system	Stroke, seizures, encephalopathy
Eyes	Blindness, scleritis
Heart	Myocardial infarction, cardiomyopathy, pericarditis, arrhythmia
Lung	Cough, chest pain, haemoptysis, shortness of breath
Kidney	Hypertension, proteinuria, haematuria, renal failure
Gastrointestinal tract	Haemorrhage, perforation
Genitals	Testicular atrophy, reduced ovarian mass

the disease and are easily detected. Small vessel vasculitis is often first noted when palpable purpura develops while the vasculitides affecting medium vessels commonly produce nodules, ulcers and gangrene.

The most common neurological manifestation of the vasculitides is mononeuritis multiplex. This is a distinctive peripheral neuropathy in which peripheral nerves infarct one at a time as a result of vasculitis in the vasa nervorum. Sudden, asynchronous and asymmetrical loss of function of individual nerves occurs, most frequently affecting sensory nerves. In the absence of diabetes and nerve compression syndromes, mononeuritis multiplex can usually be assumed to be due to a vasculitis such as polyarteritis nodosa or Wegener's granulomatosis.

INVESTIGATIONS OF VASCULITIDES

Haematological and serological changes will usually be present in individuals presenting with vasculitis. Chronic microcytic anaemia, a raised ESR and CRP are non-specific findings while red cell casts in urine, anti-nuclear antibody (ANA), complement, serum cryoglobulins and ANCA are more specific

manifestations of the vasculitides.

X-rays are generally not useful other than in Wegener's granulomatosis where views of the nasal sinuses and chest, especially using computed tomography, may demonstrate diagnostic nodular lesions.

Biopsy of involved tissues is the most helpful method of making a definitive diagnosis, especially if the biopsy is taken from a symptomatic site. Occasionally a serological test, an angiogram or another investigation can be pathognomonic.

Some investigations are helpful in excluding secondary causes of a vasculitis or those conditions that may mimic a vasculitis. Examples include investigations to exclude drug reactions, syphilis, Human Immunodeficiency Virus (HIV), infective endocarditis, and antiphospholipid syndromes. By the very nature of these conditions this list is not exhaustive.

PRINCIPLES OF TREATMENT OF VASCULITIDES

While the vasculitides are usually treated by some form of immuno-suppression, the most important principle is to make sure that the treatment intensity is commensurate with

the severity of disease.⁶ While most forms of vasculitis require aggressive treatment to prevent morbidity and mortality, some do not. For example, minor vasculitis limited to the skin or where the secondary cause of the vasculitis can be identified and subsequently can be withdrawn or treated, require no such therapy.

THE VASCULITIDES OF SPECIFIC INTEREST TO VASCULAR SURGEONS

Giant cell arteritis

Giant cell arteritis, which is also known as temporal arteritis, is the most common vasculitis found in adults. This panarteritis of the extracranial branches of the carotid artery occurs only in older individuals. The cause is unknown, but it is associated with the same HLAs found in rheumatoid arthritis and the disease process appears to be initiated by T cells in the adventitia responding to an unknown antigen.

The classic symptoms of giant cell arteritis are:⁷

- A temporal headache that is new or different (70%).
- Jaw claudication (50%).
- Polymyalgia rheumatica – which describes a condition that presents with aching and stiffness of the shoulders, neck, and hip-girdle area (40%).
- Blindness (20%). This is the most significant complication of giant cell arteritis which can however be prevented by early treatment. The visual loss is caused by occlusion of the posterior ciliary branch of the ophthalmic artery. As a result, the blindness tends to be profound but fortunately is rarely the first manifestation of this complication

and is usually preceded by episodes of diplopia and blurred vision.

- Malaise (50%).

The aorta and its major branches can also be involved (25%) leading to the development of thoracic aortic aneurysms some years after the first manifestation.

Giant cell arteritis is characterised by a raised ESR and CRP, and the presence of a normochromic, normocytic anaemia. Ultrasound of the affected temporal arteries can show a characteristic ‘halo’ of peri-vascular oedema or stenosis of the involved segments. Angiography (usually MRA or CTA) is required to demonstrate involvement of the thoracic aorta and its branches if this is suspected, while PET can demonstrate occult large-vessel inflammation. The definitive method of making the diagnosis of giant cell arteritis is by histology of the temporal artery. As a result of the risk of sudden and irreversible blindness, a temporal artery biopsy, which has a low morbidity, should be performed without hesitation to confirm the diagnosis.⁸ As the artery may be affected by skip lesions a 3 to 5cm segment of artery should be submitted for evaluation. The histology will demonstrate mononuclear cells infiltrating all layers of the artery with varying degrees of intimal proliferation and disruption of the internal elastic lamina.⁷ In recent years the possibility of using duplex ultrasonography to identify characteristic features of giant cell arteritis has been raised and further research in this area is warranted.

Treatment with high doses of prednisone (40–60mg/day) and low dose aspirin should be started immediately when the diagnosis is suspected and before it has been confirmed by the temporal artery biopsy. If visual loss has been present for a few hours very high doses of intravenous methyl-prednisolone should be given as some vision may recover. Usually,

after more than 24 hours the visual loss is permanent. In the long-term, in the presence of a normal ESR and CRP, the prednisone can be tapered at a rate determined by the clinical picture and the ESR or CRP.⁸ The effectiveness of methotrexate as a glucocorticoid-sparing drug for giant cell arteritis remains controversial while the role of biological therapies such as the tumour necrosis factor inhibitors, infliximab is unknown.

The majority of patients with giant cell arteritis will experience a relapse as the dose of prednisone is tapered and therefore prednisone will often need to be given for prolonged periods and with resultant frequent additional complications from the steroids therapy.

Surgical or endovascular interventions are occasionally indicated when the disease involves the aortic arch and its branches.

Takayasu's arteritis

This large vessel vasculitis affects mostly young adult women but has been found in infants and more rarely in the aged. The cause is unknown, yet the geographic distribution (predominantly south-east Asia, India and Africa) suggests environmental or genetic factors – e.g. HLA associations have been found in Japanese patients – while the predominance in women of childbearing age points to oestrogen and progesterone playing a role.⁷

Takayasu's arteritis is a T-cell driven, non-specific granulomatous inflammation of all layers of the vessel wall which pathologically cannot be distinguished from giant cell arteritis.⁹ In response to the inflammation, cellular proliferation in the intima and media may lead to occlusion and stenosis of the artery, or weakening of the media and adventitia which can result in dilation and aneurysm formation. The most frequently

affected vessels are the subclavian arteries, carotid arteries and the aorta, including the origin of its visceral branches. Dilatation or aneurysm formation is usually only found in the aorta. The pulmonary and coronary arteries can be involved, albeit rarely and myocarditis associated with Takayasu's arteritis has also been described.^{9,10}

The disease is usually recognised by the manifestations of the vascular disease but constitutional symptoms of inflammation – fever, myalgia, arthralgia and weight loss – are commonly the earliest feature of this illness. The vascular manifestations include those associated with occlusion of arteries supplying the limbs, hypertension caused by aortic or renal artery stenosis, cerebrovascular manifestations due to occlusion of the carotid or vertebral arteries and aortic valve regurgitation. Involvement of the coronary arteries, myocardium and pulmonary arteries may cause angina and congestive cardiac failure.⁹⁻¹¹ Affected blood vessels are often tender and as a result, severe back pain, similar to that seen in patients with thoracic dissection, and pain in the carotid arteries is common.

No specific diagnostic test exists. An elevated ESR and CRP are usual during active phases of the disease.⁹ Microcytic anaemia develops in many patients. Some patients have an elevated serum creatinine usually associated with longstanding hypertension, while glomerulonephritis occurs rarely.

Vascular imaging is essential to delineate the full extent of the vascular involvement. Many favour MRA, as this can demonstrate changes in the vessel wall prior to luminal changes being noted. PET may detect vascular inflammation but its accuracy in diagnosing the disease has not been determined but shows promise.¹²

The histological diagnosis is based on demonstrating the typical granulomatous vasculitis with giant cells in inflamed blood

vessels. This is however rarely possible, as biopsy of an affected artery while the disease is in an active phase is usually not advisable, and when specimens become available, while the disease is in a quiescent phase, only nonspecific transmural fibrosis can be found.

Initial treatment requires high doses of prednisone in the acute phase which is then tapered to 10mg/day and continued for 4 to 6 months. This regime is usually effective in addressing the inflammation in the vascular wall and abating the constitutional symptoms but two thirds of patients with Takayasu's arteritis experience relapse of symptoms or progression of vascular disease. As a consequence life-long monitoring of this condition is mandatory.

Methotrexate or mycophenolate mofetil in combination with prednisone are occasionally needed to reduce the inflammation and are also at times used without prednisone during phases of remission in order to minimise the corticosteroid side effects. Other drugs such as cyclophosphamide are used rarely because of their side effects but on occasion are all that some patients will respond to. Agents such as infliximab have shown promise but are usually unaffordable in the countries in which this disease predominates.⁹ The use of statins and low-dose aspirin is encouraged.

The renal and cardiac dysfunction and hypertension that do not rapidly resolve after initial treatment for the acute inflammatory disease are managed using standard protocols. Diagnosing and managing these can, however, be challenging because of the diffuse vascular involvement. In patients who have cerebrovascular occlusive disease it is often also necessary to maintain a high blood pressure to avoid episodes of cerebral and brainstem hypoxia. Surgical and endovascular interventions play an important role in treating occlusive and

aneurysmal manifestations.¹¹ The indications for intervention are the same as they are for other pathologies, i.e. usually only for life or limb threatening symptoms. Fortunately, few interventions are required in the acute phase, as failure rates are high for procedures performed when acute inflammation is present, are high. Revascularisation in our practice is deferred, if at all possible, until pharmacological therapy has completely suppressed the inflammation, which we believe to be indicated by a normal CRP and ESR. This experience is shared by others.¹³

In the long-term once the active disease has been treated, most patients return to near normal lifestyles and survival rates. A significant number of patients do however die as a consequence of renal or cardiac failure,¹⁴ or from the complications of immunosuppressive treatment which is compounded by the high prevalence of HIV infections in some of the affected populations.¹¹

Thromboangiitis obliterans (Buerger's disease)

This condition usually occurs in young individuals after extended and ongoing exposure to tobacco smoke, but can affect all age groups. The reason for the relationship between thromboangiitis obliterans and smoking has not been established. There are some indications that it has an immunological background, as increased levels of cell-mediated responses to vascular collagen and raised levels of anti-endothelial cell antibodies have been described.¹⁵ Other forms of smoking, such as cannabis, may also cause similar disease patterns.

Thromboangiitis obliterans affects medium-sized arteries, veins and nerves. The lower limbs are most frequently affected but upper limb disease is common. Pathologically, the blood vessel wall architecture is usually

intact, with preservation of the internal elastic lamina and absence of necrosis. During the acute phase of the disease a highly cellular, inflammatory thrombus is found occluding the lumen. In time this becomes a band of fibrous tissue. Involvement of superficial veins is associated with a perivascular inflammatory cell infiltrate resulting in a thrombophlebitis.

Thromboangiitis obliterans is usually first recognised by the presence of extremely painful, severe, progressive digital ischemia (often first thought to be splinter haemorrhages).¹⁵ Occasionally, the earliest lesion may be a superficial thrombophlebitis. In advanced cases the gangrene may extend well beyond the digits. Other organs are not involved. Prior to the development of gangrene, pain in the distal extremities may be due to a neuropathy. These symptoms are due to thickening of the tissues in the neurovascular bundles as a result of perivascular inflammation.

The diagnosis is generally confirmed by identification of the typical pattern of vascular involvement, exclusion of conditions that may mimic the disease, particularly atherosclerosis, and the presence of ongoing tobacco exposure. The demonstration of typical 'corkscrew' collaterals in the neurovascular bundles is characteristic but can also be found in other conditions such as diabetes mellitus and polyarteritis nodosa.¹⁵ While most diagnostic systems for thromboangiitis obliterans are intended to exclude the presence of atherosclerosis, both these conditions often coexist, particularly in patients over the age of 40 years.

The only effective treatment for thromboangiitis obliterans is to completely stop smoking.¹⁵ Immunosuppression and anticoagulation have no role. Occasional patients respond partially to prostaglandins. Revascularisation, using endovascular techniques or bypass grafts, is usually not feasible

from a technical perspective, as a result of the inflammatory and thrombotic processes, and occlusion of distal runoff arteries, but may play a role if haemodynamically significant atherosclerotic lesions coexist in the patient. Effective pain control is essential as patients will not be able to stop smoking without it.

With any ongoing smoking, which tends to be the norm – such patients appear to be particularly nicotine dependent – arterial disease progresses. Limb loss therefore occurs frequently. On the other hand, complete abstinence is associated with remarkably good outcomes.

Behçet's disease

Behçet's disease was originally described as a syndrome consisting of recurrent oral aphthous ulcers, genital ulcers, and ocular inflammation. This idiopathic vasculitis can however, cause inflammation in almost any organ. The most significant morbidity associated with Behçet's disease is related to ocular inflammation, which can cause blindness. Most manifestations of the disease are however episodic and become less frequent over time, but mortality may occur – mostly as a result of thrombosis, aneurysms and de novo rupture of large vessels.

Behçet's disease is common in countries along the ancient Silk Road (eastern Mediterranean countries central Asia to China) – as many as 4 per 1000 population have been described – and rare elsewhere. It mostly affects young adults and is more frequent in men. The distinct geographic distribution suggests an environmental or genetic aetiology. The pathologic changes point to an abnormal reactivity of neutrophils and lymphocytes causing damage by a vasculitic process which affects all types of arteries. Venous thrombosis is also common.¹⁶

Clinically, oral ulceration tends to be the earliest manifestation and must be present to make the diagnosis of Behçet's disease. These painful ulcers, which affect the mucosa from the lips to the oropharynx, can be up to 2cm in diameter and usually have a white base and a red halo around the ulcer. Between two and five lesions are usually present at a time. The oral lesions tend to heal within two to three weeks without scarring while the genital ulcers tend to be larger and deeper, and often heal with scarring. In men the genital ulcers, which develop mostly on the scrotum and less commonly on the shaft of the penis, are associated with epididymitis. In women ulcers affect the vagina and vulva. Ocular inflammation is caused by an anterior and posterior uveitis. The anterior uveitis usually presents with a red eye, photophobia and blurred vision while the less common posterior uveitis, in combination with vasculitis affecting the carotid arteries and retina, can result in loss of vision. Other regularly encountered features include erythema nodosum, migratory thrombophlebitis, arthritis, spondylitis, gastrointestinal aphthous ulcers, meningo-encephalitis, stroke (thrombotic or haemorrhagic), sagittal sinus thrombosis, seizures, hearing and vestibular impairment, dementia and psychiatric conditions. Vascular manifestations, include thrombophlebitis and venous thrombo-embolism, occur in a fifth of patients while the arterial vasculitic manifestations are much less common – this arterial process particularly affects mesenteric and pulmonary arteries and may cause occlusion, aneurysm formation or primary rupture.^{17,18}

The diagnosis of Behçet's disease rests predominantly on the clinical features but raised nonspecific markers of inflammation are common while the disease is active. Serum IgD levels are also often elevated. Histology of the aphthous ulcers reveals an

inflammatory vascular infiltrate but a true vasculitis is rare.¹⁶

The oral ulcers and other aphthous lesions are treated with topical steroids or Dapsone while vision- or life- threatening complications are treated with high doses of intravenous corticosteroids and other immunosuppressive agents. Infliximab is also effective.¹⁶ Vascular interventions are required for symptomatic life threatening occlusive arterial disease, while aneurysms are treated according to their risk of rupture. All spontaneous arterial ruptures require emergency repair. Thrombophlebitis is treated symptomatically and venous thrombo-embolism is managed by anticoagulation.

Polyarteritis nodosa

This is a vasculitis confined to small and medium-sized arteries. Men and women are equally affected and the disease occurs in all age and ethnic groups. The association with chronic hepatitis B virus infection is well established.¹⁹

Polyarteritis nodosa can involve virtually all organs, but spares the lungs.²⁰ Commonly involved organs are:

- Skin – includes livedo reticularis, nodules, papules, ulceration, and digital ischemia often associated with splinter haemorrhages which can lead to gangrene.
- Peripheral nerves – usually mononeuritis multiplex of the sural, peroneal, radial, and ulnar nerves.
- Gastrointestinal tract – commonly postprandial abdominal pain, but also mesenteric infarction or aneurysmal rupture of visceral arteries due to multiple microaneurysms.
- Kidneys – excluding glomerulonephritis.

The constitutional symptoms of inflammation and pain, caused by myalgia, arthritis,

peripheral nerve infarction, testicular ischemia, or mesenteric vasculitis, are usually found. The other vascular presentations include renin-mediated hypertension, sub-clinical arteriolar involvement of the cardiac circulation with occasional congestive cardiac failure and myocardial infarction, and occasional stroke.

The diagnosis of polyarteritis nodosa is generally based on histology – most frequently of skin nodules, which specifically does not demonstrate granulomatous infarction – and the demonstration of microaneurysms in the visceral arteries. The ANA and rheumatoid factor (RF) are usually negative. The ANCA tends to be positive but specific enzyme immunoassays for antibodies to proteinase-3 or myeloperoxidase – the antigens known to be associated with systemic vasculitis – are negative. Polyarteritis nodosa is therefore not considered to be an ANCA associated vasculitis.

When polyarteritis nodosa is associated with hepatitis B virus, polyarteritis nodosa tends to occur soon after the initial infection and these patients also have low complement levels.

Treatment of idiopathic polyarteritis nodosa is similar to the other vasculitides already described.²⁰ Cyclophosphamide is required for approximately half the patients whose disease is refractory to corticosteroids or who have significant life threatening involvement of major organs. Hepatitis B virus if present is treated with antiviral therapy which is the reason that the frequency of polyarteritis nodosa is diminishing.

The prognosis is usually favourable. Bowel perforation and rupture of a mesenteric microaneurysm however requires emergency surgical intervention which is the reason that this disease still causes mortality. Recurrence rates after successful treatment of the initial clinical manifestation are unusual.

Vasculitis secondary to connective tissue diseases

Systemic lupus erythematosus (SLE)

In SLE, lupus vasculopathy is found in up to 40% of patients (mostly female). This usually is a typical vasculitis characterised by inflammation and necrosis in the vessel wall.²¹ The aetiology of these changes are:

- Leucocytoclastic inflammation in 60%
- Cryoglobulinaemia in 30%
- Systemic vasculitis resembling polyarteritis nodosa in 6%.

Lupus vasculitis is also associated with thrombotic thrombocytopenic purpura, venous thrombosis, antiphospholipid syndrome and urticarial vasculitis.

Lupus vasculopathy is an immunological disease with various autoantibodies, directly or indirectly affecting endothelial cells and cell membrane phospholipids. These cause chronic vessel wall damage.²² It is hypothesised that the endothelial deposition of circulating immune complexes causes activation of secondary inflammatory responses which then activate the complement cascade. This results in the destruction of vascular basal membranes. The expression and activation of adhesion molecules appear to also be the key factors in the pathogenesis of the vasculitis by enabling leukocyte adhesion to the vessel endothelium and allowing leukocyte infiltration into affected tissues. In addition, lupus vasculitis also initiates the development and progression of atherosclerosis.

The antibodies involved in lupus vasculitis include:^{22,23}

- Anti-endothelial cell antibodies which occur in over 80% of SLE patients. It seems that their presence is typical of vasculitis, vascular thrombosis and lupus nephritis. These antibodies belong to

the IgG, IgM and IgA immunoglobulins and bind to antigens through the F(ab)2 region. Multiple endothelial cell antigens react with these antibodies.

- Antiphospholipid antibodies which bind to exposed endothelial cell phospholipids. These antibodies cause vascular endothelial damage, an increased arterial and venous thrombosis risk and proliferative heart valve lesions.
- ANCA. Their role in lupus vasculitis remains unclear.
- Anti-double-stranded DNA antibodies may take part in vascular damage in SLE. They possess an anti-endothelial activity, which is directed against certain antigens on the endothelial surface.

The spectrum of the lupus vasculopathy ranges from the mild and most common form, affecting only vessels of the skin, to severe multiple organ dysfunction.²¹ The cutaneous lupus vasculopathy manifests as purpura, urticaria or bullous lesions in the extremities, and livedo reticularis on the trunk. Occasionally necrosis of the nail bed and digital ulceration is also found. Lupus vasculitis in other organs can affect 20% of patients. Examples include:

- Focal segmental glomerulonephritis in the kidneys
- Necrotic inflammation in alveolar capillaries of the lungs
- Cognitive dysfunction, psychosis, convulsions and strokes in the brain
- Mononeuropathies in the peripheral nerves
- Gastrointestinal haemorrhage or perforation.

Antiphospholipid antibody syndrome (APS)

The APS is defined by the presence of at least one of the many plasma antiphospholipid

antibodies and the occurrence of at least one clinical feature of which venous or arterial thromboses, recurrent foetal loss, or thrombocytopenia are the most common. The antiphospholipid antibodies, which are directed against plasma proteins bound to anionic phospholipids, are:^{24,25}

- Lupus anticoagulants. These are antibodies directed against plasma proteins such as β 2 glycoprotein-1 or prothrombin bound to anionic phospholipids. Despite their name, the presence of lupus anticoagulants is generally associated with thrombosis and they do not have an anticoagulant effect.
- Anticardiolipin antibodies.
- Other antibodies, e.g. those to β 2 glycoprotein-I, prothrombin, annexin V, phosphatidylserine and phosphatidylinositol.

In addition to causing thrombosis, the above antibodies also increase vascular tone, thereby increasing the susceptibility to atherosclerosis, fetal loss and neurological damage.

The pathogenesis remains unclear. It appears that the antiphospholipid antibodies develop in susceptible individuals following incidental exposure to currently undefined, infectious agents. Once the antibodies are present a second hit, such as an infection, prolonged immobilisation, pregnancy, hormone replacement therapy, malignancy or nephrotic syndrome is required for the syndrome to develop.²⁴

APS can either be a primary disease or can be associated with another secondary condition.²⁵ For example:

- Some healthy individuals have antiphospholipid antibodies but few ever get the APS.
- Autoimmune diseases – particularly SLE.

- Infections:
 - Bacterial infections: e.g. bacterial septicaemia, tuberculosis, leprosy and post-streptococcal rheumatic fever.
 - Viral infections: e.g. hepatitis A, B, and C, HIV, cytomegalovirus and Epstein-Barr virus.
 - Parasitic infections: malaria and visceral leishmaniasis
- Medications: e.g. phenothiazines, phenytoin, hydralazine, α -interferon, quinine, amoxicillin, chlorthiazide, oral contraceptives and propranolol.
- Malignancies including solid tumours of the lung, colon, cervix, prostate, kidney, ovary, breast, and bone; Hodgkin's and non-Hodgkin's lymphoma; myelofibrosis, polycythemia rubra vera, myeloid and lymphocytic leukemias.

The most common manifestations, in order of frequency, are deep vein thrombosis, thrombocytopenia, livedo reticularis, stroke, superficial thrombophlebitis, pulmonary embolism, fetal loss, transient ischemic attack and haemolytic anaemia. Rarely, APS results in ischaemic multiorgan failure. Other possible antiphospholipid antibodies related manifestations include migraine headache, Raynaud's phenomenon, pulmonary hypertension, avascular necrosis, cutaneous ulcers that resemble pyoderma gangrenosum, adrenal insufficiency and cognitive deficits.

The presence of APS should be considered in patients who have one or more otherwise unexplained thrombotic or thrombo-embolic events, one or more adverse outcomes related to pregnancy or otherwise unexplained thrombocytopenia or bleeding.

Rheumatoid arthritis

The vasculitis associated with rheumatoid arthritis occurs in patients with previously severe disease, typically in those with long-standing rheumatoid nodules, destructive

joint disease, and high titres of rheumatoid factor. The development of a vasculitis is associated with new constitutional symptoms, skin ulceration, serositis, digital ischemia, and sensory and motor nerve dysfunction. It may also cause multiorgan dysfunction.

The vasculitis is caused by the deposition of immune complexes and antibody-mediated destruction of endothelial cells resulting in vascular necrosis and luminal thrombosis.²² Cigarette smoking and other factors have a significant adjunctive role.

The diagnosis should ideally be established by tissue biopsy. Deep full-thickness skin biopsies from the edge of skin ulcers, that include some subcutaneous fat, can detect the presence of medium-vessel vasculitis.

As in all the vasculitides, therapy must reflect the severity of organ involvement. When small, relatively painless infarctions around the nail bed develop, these do not necessarily require treatment. While this vasculitis does respond to therapy it generally is associated with a poor prognosis. Fortunately, with the modern more effective treatment of rheumatoid arthritis, this condition is becoming rare.²⁶

Scleroderma

Scleroderma refers to the presence of thickened, hardened skin which is a common feature of a heterogeneous group of connective tissue disorders. When the characteristic skin disorder is associated with visceral organ involvement, the disease is termed systemic sclerosis. This is further subcategorised into diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis on the basis of the extent and distribution of the skin involvement. Limited systemic sclerosis is commonly associated with the CREST syndrome (made up of cutaneous calcification, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, and telangiectasia).

The visceral manifestations of systemic sclerosis are varied, including fibrotic and/or vascular complications of the circulatory, musculoskeletal, renal, pulmonary, and gastrointestinal systems. The characteristic clinical manifestation of vascular dysfunction is Raynaud's phenomenon.²⁷ Episodes of Raynaud's phenomenon may be prolonged and can result in ischemic digital ulceration or infarction. In patients with limited cutaneous systemic sclerosis, Raynaud's phenomenon generally precedes other disease manifestations, often by many years. In contrast, in patients with diffuse cutaneous systemic sclerosis, the onset of Raynaud's phenomenon generally coincides with, and in some cases may even follow, the appearance of characteristic skin or musculoskeletal manifestations. Vascular injury and consequent chronic tissue damage underlies other serious complications of systemic sclerosis, including pulmonary artery hypertension, renal crisis and gastric antral vascular ectasia, and also contributes to the pathogenesis of cardiac and other gastrointestinal complications.²⁸

The presence of systemic sclerosis is suggested by the presence of skin thickening and hardening that is not confined to one area. The diagnosis is supported by the presence of other non-cutaneous features such as:

- Heartburn and/or dysphagia
- Acute onset of hypertension and renal dysfunction
- Effort induced dyspnoea and interstitial pulmonary fibrosis
- Pulmonary hypertension
- Mucocutaneous telangiectasia on the face, lips, oral cavity, or hands
- Digital gangrene

Over 95% of patients have at least one autoantibody present. These include the

presence of antinuclear antibodies and more specific antibodies such as anti-topoisomerase I, anti-centromere, anti-RNA polymerase III and anti-beta2-glycoprotein I antibodies which are frequently present in patients with systemic sclerosis. The anti-topoisomerase I, anti-centromere and anti-RNA polymerase III antibodies are specific but only moderately sensitive. A skin biopsy is generally not needed to confirm a diagnosis.

Infective vasculitides

Human immunodeficiency virus (HIV)

HIV infection can cause a range of vascular diseases.²⁹ In the arterial system, HIV positive patients have been found to have both aneurysms and occlusive disease, mostly thrombotic disease. These vessel wall pathologies have unique histological characteristics where the inflammation is found in the vasa vasora. The inflammatory process consists of neutrophils surrounded by a cuff of plasma cells and lymphocytes. In addition, there is marked endothelial swelling with fibrin deposits on the luminal surface which leads to occlusion of the vasa vasora. In the wall of large arteries there are patches with acute inflammatory infiltrate, while in other regions there are areas of extensive fibrosis without inflammation. This suggests that there is a sequence of events starting with inflammation concentrated in the adventitia. Later in the disease this may either cause trans-mural necrosis, possibly leading to aneurysm formation, or the transmural inflammation may induce luminal thrombus.

Both HIV associated aneurysms and HIV associated arterial occlusion are considered to be Acquired Immunodeficiency Syndrome (AIDS) defining conditions as they are usually associated with low CD4 counts in patients with other manifestations of the infection.

HIV associated aneurysms have been found in most major arteries and are usually saccular in nature as a result of a localized region of cytoelastic activity in all layers of the arterial wall. Patients tend to present with multiple aneurysms. Treatment is based on the usual principles of care for aneurysms but because of the poor general condition of affected patients, endovascular modalities are favoured.

Occlusive arterial disease most commonly involves the iliac arteries, but involvement of the coronary arteries is also found in young men who also smoke.³⁰ Treatment of these patients is hampered by the underlying vasculitis and is generally associated with a poor outcome unless the inflammatory process is reversed by treating the HIV infection.

The association between venous thrombo-embolism and the HIV infection has also been conclusively proven.³¹ The reported incidence ranges from 0.2% to 18% which is well in excess of what one would expect in a non-infected population (0.05%). At the Johannesburg Hospital 84% of patients who presented with deep vein thrombosis were found to be HIV positive. The severity of the HIV infection appears to be of significance as there is a greater incidence of venous thrombosis in patients with low CD4 counts, while the risk is even higher when individuals have confirmed AIDS. The reason for HIV infection's relationship with venous thrombosis has not yet been conclusively elucidated, but appears to be multimodal, with all three limbs of Virchow's triad being involved.

PATHOPHYSIOLOGY AND PRINCIPLES OF TREATMENT OF RAYNAUD'S PHENOMENON

In order to preserve the core temperature, the normal physiological response to exposure

to a cold environment is to reduce capillary blood flow to the skin, mostly in the limbs and digits. This response is regulated by a complex interaction of neural signals, circulating hormones, and the release of local mediators mostly derived from the vascular endothelium.

Raynaud's phenomenon describes an exaggerated vascular response to such a cold stimulus, or occasionally to emotional stress. The phenomenon is characterised by sharply demarcated colour changes of the skin of the digits. Typically these consist initially of a phase of vasoconstriction and therefore a pale appearance (white) followed in time by cyanosis (blue) as a result of deoxygenation of haemoglobin within the affected tissues. Finally, with reflex vasodilation as a result of the localised tissue ischaemia and the resultant inflow of oxygenated blood, a phase of hyperaemia (red) follows. Only the two initial phases, pallor and cyanosis, need to have been present for such an event to be recognised as a Raynaud's attack.³²

Primary Raynaud's phenomenon describes this sequence of events in the absence of any associated disorders – occasionally called Raynaud's disease, which is inappropriate as the phenomenon only describes an exaggerated physiological response in these individuals – while secondary Raynaud's phenomenon is associated with a known disease –referred to occasionally as Raynaud's syndrome (Table 16.3).³³

The defect in primary Raynaud's phenomenon is currently thought to be an increased vasoconstrictive response to α_2 adrenergic stimuli, particularly at the level of α_2 adrenergic receptors, in the digital arteries and cutaneous arterioles.³⁴ The exact mechanisms have however not yet been established. The vascular response to the α_2 adrenergic agonists, serotonin and angiotensin II is increased during cooling and can be reversed by tyrosine kinase inhibitors.³⁵

TABLE 16.3: Common secondary causes of Raynaud's phenomenon^{32,33,36}

Connective tissue diseases and vasculitis:	
Systemic lupus erythematosus	Systemic sclerosis (scleroderma)
Rheumatoid arthritis	Giant cell arteritis
Thromboangiitis obliterans	Primary biliary cirrhosis
Diseases of arteries in the upper limbs:	
Atherosclerotic occlusive disease	Frost bite
Thoracic outlet syndrome	
Malignancies:	
Ovarian carcinoma	
Endocrine diseases:	
Phaeochromocytoma	Thyroid disease
Carcinoid syndrome	
Vasospastic conditions:	
Vibration syndromes	Migraine and Prinzmetal angina
Haematological disorders:	
Cryoglobulins and cold agglutinins	Polycythaemia
Paraproteinaemia	
Drugs and chemicals:	
Ergotamines	Polyvinyl chloride
Bleomycin and Vinblastine	

An underlying genetic mechanism is also suggested by the occasional appearance of Raynaud's phenomenon in family clusters, and because women are most frequently afflicted by this condition, suggesting that some of the relevant loci are located on the X chromosome. The effect of oestrogen on α_2 adrenergic receptor expression may however also be a reason for the higher prevalence of this condition amongst women.³⁵

In secondary Raynaud's phenomenon, the many diseases, drugs, and environmental factors that can cause the syndrome, disrupt the normal mechanisms responsible for control of vessel reactivity, each apparently in a unique manner. For example, in systemic sclerosis (scleroderma) the primary mechanism is considered to be associated with intimal fibrosis and endothelial dysfunction. In these patients, endothelin-1 levels are significantly increased. This potent vasoconstrictor is also involved in the development of fibrosis and other structural changes in blood vessels.³⁵ In

addition, angiotensin II levels are increased, while nitric oxide levels are consistently found to be low.

Prevalence of Raynaud's Phenomenon

It is difficult to establish the prevalence of Raynaud's phenomenon because of the lack of standardisation in the diagnosis. However, when using at least pallor and cyanosis to define an episode of Raynaud's phenomenon, the prevalence ranges from 3 to 20% in women and 3 to 14% in men.³³ These wide ranges are explained by the great variation found across the world both in populations and in climate. For example Raynaud's phenomenon is common in central Europe when compared to populations in the Americas, Africa and Asia. It is also more common among women, in younger age groups (median onset 14 years), and in family members of individuals with

established Raynaud's phenomenon. About 25% of individuals first develop symptoms after the age of 40 years and rarely after the age of 60 years.³²

Clinical Findings in Raynaud's Phenomenon

Raynaud's phenomenon most frequently affects the fingers and hands. While the toes and feet are often also affected this tends not to concern patients as much. A typical episode usually begins in a single finger and then spreads to all other digits but the thumbs are often spared. Vasospasm of the skin of the ears, nose, face, knees and nipples is also commonly described. The ischaemic phase (pallor and cyanosis) usually lasts for 15 to 20 minutes. Often when the initial phase of such an attack is prolonged, patients describe the feeling of pins and needles, numbness, and complain that the fingers are aching. These symptoms rapidly reverse in patients with primary Raynaud's phenomenon when the limb is rewarmed or the stress is alleviated. On the other hand in secondary Raynaud's phenomenon, asymmetry of symptoms, severe constant pain and ischaemic ulceration of the skin may occur, particularly when the mechanism of the underlying disease cannot be addressed.

Exposure to cold is the usual trigger and mostly occurs with rapid movement from a warmer to a cooler environment. As a consequence, air-conditioned rooms, or the mere washing of hands in cold water may be all it takes to bring on an episode. An attack is usually brought on by the distal limbs being exposed, but on occasion cooling of the trunk while the hands or feet areas are kept warm can also provoke an attack. As a consequence afflicted individuals should always ensure that all parts of their body are kept warm.

Diagnosis of Raynaud's Phenomenon

The diagnosis is mostly made when the classic symptoms are described. Confirming the diagnosis by using provocative manoeuvres such as a cold water challenge, is unhelpful due to inconsistency in producing the syndrome. As the majority of patients presenting with Raynaud's phenomenon have no other underlying disease little benefit is achieved by further evaluation.

In the small number of individuals who have a secondary cause or in whom symptoms persist, additional evaluation may be helpful, but this usually requires complex diagnostic tools that are generally not freely available. The tools used to assess the vascular responses to environmental stimuli in the skin, include nail fold capillaroscopy, angiography, laser Doppler flowmetry, and measurement of skin temperature. Generally, in patients with all forms of Raynaud's phenomenon these demonstrate that there is a delayed recovery phase of vascular flow after exposure to environmental stressors.^{32,33}

Every patient with primary Raynaud's phenomenon should be carefully evaluated clinically, to exclude a secondary cause.³² The criteria to diagnose primary Raynaud's phenomenon include the presence of symmetrical, episodic attacks, no evidence of occlusive arterial disease, no gangrene, and if there is doubt a negative nail fold capillary examination (if this is available), a negative ANA and normal ESR/CRP. The clinical clues that secondary Raynaud's phenomenon may be present include:

- Age of onset >40 years
- Male
- Pain and tissue ischemia (ulceration)
- Asymmetry

The presence of a raised ESR or CRP and autoantibodies suggests an underlying connective tissue disease.

PROGNOSIS

Approximately 50% of individuals with primary Raynaud's phenomenon will have a reduction in the frequency and severity of their symptoms over time, particularly if the onset of symptoms occurs in adolescence.

Occasionally, Raynaud's phenomenon is the first manifestation of an underlying disease. The frequency at which individuals thought to initially have primary Raynaud's phenomenon are found to have a underlying cause identified is in the region of 1% per year, but is usually only noted 10 years or more after the primary presentation. The best predictor that this may happen is an abnormal nail fold capillary pattern.³⁶

TREATMENT

The initial management of patients with primary Raynaud's phenomenon is to promote lifestyle changes and to avoid the use of medication.³⁶ The advice usually given includes:

- Keeping the whole body warm by:
 - Avoiding sudden exposure to cold
 - Dressing warmly
 - Keeping all digits warm even in very cold environments
 - Avoiding rapidly changing temperatures
- Reducing emotional stress
- Avoid smoking and using drugs that cause vasoconstriction

If an attack occurs, the patient should be advised to go to a warm room and to place the hands under warm water, or to swing the upper limbs like a windmill.

In patients with secondary Raynaud's phenomenon the above measures are less helpful, as a result of more severe attacks. For this reason, and because of the progression of the ischaemia, they will usually require pharmacological intervention as do some patients with primary Raynaud's phenomenon in whom severe symptoms persist.

Multiple classes of drugs are used in the management of Raynaud's phenomenon. The medications used are:³⁷

- Calcium channel blockers. Approximately 60% of patients have a clinically significant improvement of their symptoms (both in the reduction of the severity and frequency).⁷ Not all calcium channel blockers are effective. Nifedipine in relatively small doses given three to four times per day is the one most frequently used. These drugs are introduced slowly in order to reduce the chance of patients experiencing headaches. Secondary Raynaud's phenomenon is also less likely to benefit from this class of drugs.
- Many direct and indirect vasodilators have some effect but few are freely available for the management of this condition. The serotonin reuptake inhibitors (such as fluoxetine), angiotensin receptor blockers (losartan) and other vasodilators such as buflomedil have demonstrated similar response rates when compared to the effective calcium channel antagonists.
- Prostaglandins. Prostaglandin E1 (PGE1), prostacyclin (PGI2), and iloprost (a PGI2 analogue) are the most frequently used. The response rate in severely affected patients is in the region of 60%. Infusions given over a few days often have benefit that often lasts several months.
- The phosphodiesterase inhibitors, sildenafil and tadalafil. The current data

supporting the use of these agents is sparse but promising.

- Endothelin receptor antagonists e.g. bosentan which acts as an antagonist of endothelin-B receptors, has been demonstrated to significantly reduce the number of new ulcers forming in patients with systemic sclerosis.
- Antioxidant agents, such as zinc gluconate and N-acetylcysteine have demonstrated some improvement in small studies
- Atorvastatin does reduce the severity and frequency of Raynaud's events and of ulcer formation in patients with scleroderma.

In addition, multiple antithrombotic agents have been utilised in patients with significant complications associated with Raynaud's phenomenon. These include aspirin, dipyridamole, systemic anticoagulation, and thrombolytic therapy. The benefit of antiplatelet therapy with aspirin (75 or 81mg/day) is uncertain but use of this agent should be considered in all patients with secondary Raynaud's phenomenon.

The role of sympathectomy has recently again been considered in the management of severe Raynaud's phenomenon mostly as a result of the development of less invasive and more focused procedures being available.³⁶ These include:

- A local chemical sympathectomy using a long acting local anaesthetic agent to achieve a wrist or digital nerve block which can reverse vasoconstriction and relieves pain.
- Intradigital botulinum toxin A has been used to achieve a chemical sympathectomy. While this is an interesting option, the current described experience is limited.³⁷
- Cervical sympathectomy is likely to result in the immediate improvement in blood flow, but the degree and duration

of improvement is very variable and long term outcomes particularly in patients with secondary Raynaud's phenomenon are poor.

- Localised microsurgical digital sympathectomy has been introduced as an alternative to proximal sympathectomy. This option appears to have more durable outcomes and is often now the choice when sympathectomy is the last treatment modality available, particularly only after vasodilator drugs and after specific treatments for any reversible cause, such as vasculitis, have failed.

RECOMMENDATIONS

All patients with Raynaud's phenomenon should avoid cold temperatures, stress, and vasoconstrictors, while always being dressed in warm clothing, and should warm their hands in order to terminate an attack.

Most importantly, patients with primary uncomplicated Raynaud's phenomenon should not be over-treated. Therapy should only be initiated in those patients with primary uncomplicated Raynaud's phenomenon in whom non-pharmacologic measures have failed. These medications should be introduced in a step wise manner and should only be continued if appropriate symptom relief is achieved. Parenteral medications and sympathectomy are usually not indicated.


Patients with secondary Raynaud's phenomenon may require more aggressive therapy. The major goal is to reduce the frequency of attacks, and to prevent digital ulceration. It is unlikely that any medical therapy on its own will completely terminate attacks. In general, a step wise escalation of therapy, initially using the oral vasodilators, followed by parenteral medications and lastly localised digital sympathectomy, should be used in accordance to the level of symptoms

and the extent of digital ulceration and gangrene. All such patients should also have the underlying disease addressed, which in patients with the vasculitides include the use of a statin and an antiplatelet agent. In addition appropriate and effective analgesia will be required. Such pain control and surgical amputation may be the only option in patients with late stage ischemia or severe structural arterial disease.

REFERENCES AND SUGGESTED READING

1. Watts RA, Scott DG. Recent developments in the classification and assessment of vasculitis. *Best Pract Res Clin Rheumatol.* 2009; **23**: 429–43.
2. Savige J, Davies D, Falk RJ, et al. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. *Kidney Int* 2000; **57**: 846–62.
3. Watts RA, Suppiah R, Merkel PA, Luqman R. Systemic vasculitis – is it time to reclassify? *Rheumatology (Oxford)* 2010; **50**: 643–5.
4. Liu LJ, Chen M, Yu F, et al. Evaluation of a new algorithm in classification of systemic vasculitis. *Rheumatology (Oxford)* 2008; **47**: 708–12.
5. Kallenberg CG. The last classification of vasculitis. *Clin Rev Allergy Immunol* 2008; **35**: 5–10.
6. Watts RA, Scott DGI, Pusey CD, Lockwood CM. Vasculitis – aims of therapy. An overview. *Rheumatology (Oxford)* 2000; **39**: 229–32.
7. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. *N Engl J Med* 2003; **349**: 160–9.
8. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. *Ann Intern Med.* 2003; **139**: 505–15.
9. Tann OR, Tulloh RMR, Hamilton MCK. Takayasu's disease: a review. *Cardiol Young* 2008; **18**: 250–9.
10. Rav-Acha M, Plot L, Peled N, Amital H. Coronary involvement in Takayasu's arteritis. *Autoimmun Rev* 2007; **6**: 566–71.
11. Reddy E, Robbs JV. Surgical management of Takayasu's arteritis in children and adolescents. *Cardiovasc J Afr* 2007; **18**: 393–6.
12. Andrews J, Mason JC. Takayasu's arteritis – recent advances in imaging offer promise. *Rheumatology (Oxford)* 2007; **46**: 6–15.
13. Parra JR, Perler BA. Takayasu's disease. *Semin Vasc Surg* 2003; **16**: 200–8.
14. Maksimowicz-McKinnon K, Hoffman GS. Takayasu arteritis: what is the long-term prognosis? *Rheum Dis Clin North Am* 2007; **33**: 777–86.
15. Mills JL. Buerger's disease in the 21st century: Diagnosis, clinical features and therapy. *Semin Vasc Surg* 2003; **16**: 179–89.
16. Mendes D, Correia M, Barbedo M, et al. Behçet's disease – a contemporary review. *J Autoimmun* 2009; **32**: 178–88.
17. Yurdakul S, Yazici H. Behçet's syndrome. *Best Pract Res Clin Rheumatol* 2008; **22**: 793–09.
18. Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. *Nat Clin Pract Rheumatol* 2007; **3**: 148–55.
19. Maya R, Gershwin ME, Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. *Clin Rev Allergy Immunol* 2008; **34**: 85–102.
20. Stone JH. Polyarteritis Nodosa. *JAMA* 2002; **288**: 1632–9.
21. Calamia KT, Balabanova M. Vasculitis in systemic lupus erythematosus. *Clin Dermat* 2004; **22**: 148–56.

22. Guillevin L, Dörner T. Vasculitis: mechanisms involved and clinical manifestations. *Arthritis Res Ther* 2007; **9**: S9.
23. Cieslik P, Hrycek A, Klucinski P. Vasculopathy and vasculitis in systemic lupus erythematosus. *Pol Arch Med Wewn* 2008; **118**: 57–63.
24. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. *Clin Exp Immunol* 2004; **136**: 393–401.
25. Koniari I, Siminelakis SN, Baikoussis NG, et al. Antiphospholipid syndrome; its implications in cardiovascular diseases: a review. *J Cardiothorac Surg* 2010; **5**: 101.
26. Watts RA, Mooney J, Lane SE, Scott DGI. Rheumatoid vasculitis: becoming extinct? *Rheumatology (Oxford)* 2004; **43**: 920–3.
27. Varga J. Systemic sclerosis. An update. *Bull NYU Hosp Jt Dis* 2008; **66**: 198–202.
28. Phillip R, Luqmani R. Mortality in systemic vasculitis: a systematic review. *Clin Exp Rheumatol* 2008; **26**: S94–104.
29. Robbs JV. Pathogenesis and pathology of HIV-related large-vessel disease. *S Afr J Surg* 2009; **47**: 44–5.
30. van Marle J, Mistry PP, Botes K. HIV-occlusive vascular disease. *S Afr J Surg* 2009; **47**: 36–42.
31. Eyal A, Veller M. HIV and venous thrombotic events. *S Afr J Surg* 2009; **47**: 54–6.
32. Wigley FM. Raynaud's phenomenon. *N Engl J Med* 2002; **347**: 1001–8.
33. Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001; **357**: 2042–48.
34. Cooke JP, Marshall JM. Mechanisms of Raynaud's disease. *Vasc Med* 2005; **10**: 293–7.
35. Baumhäkel M, Böhm M. Recent achievements in the management of Raynaud's phenomenon. *Vasc Health Risk Manag* 2010; **6**: 207–14.
36. Bakst R, Merola JF, Franks AG, Sanchez M. Raynaud's phenomenon: Pathogenesis and management. *J Am Acad Dermatol* 2008; **59**: 33–53.
37. Levien TL. Advances in the treatment of Raynaud's phenomenon. *Vasc Health Risk Manag* 2010; **6**: 167–77.
38. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. *Rheumatology* 2005; **44**: 145–50.



Cover diagram by David Heinrich of the *Medical Illustration and Media Unit, Flinders Medical Centre*. (See chapter 18)

MECHANISMS OF VASCULAR DISEASE

Edited by Robert Fitridge and Matthew Thompson

Chapter 1: Endothelium **Chapter 2:** Vascular smooth muscle structure and function **Chapter 3:** Atherosclerosis **Chapter 4:** Mechanisms of plaque rupture **Chapter 5:** Current and emerging therapies in atheroprotection **Chapter 6:** Molecular approaches to revascularisation in peripheral vascular disease **Chapter 7:** Biology of restenosis and targets for intervention **Chapter 8:** Vascular arterial haemodynamics **Chapter 9:** Physiological haemostasis **Chapter 10:** Hypercoagulable states **Chapter 11:** Platelets in the pathogenesis of vascular disease and their role as a therapeutic target **Chapter 12:** Pathogenesis of aortic aneurysms **Chapter 13:** Pharmacological treatment of aneurysms **Chapter 14:** Aortic dissection and connective tissue disorders **Chapter 15:** Biomarkers in vascular disease **Chapter 16:** Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon **Chapter 17:** SIRS, sepsis and multiorgan failure **Chapter 18:** Pathophysiology of reperfusion injury **Chapter 19:** Compartment syndrome **Chapter 20:** Pathophysiology of pain **Chapter 21:** Postamputation pain **Chapter 22:** Treatment of neuropathic pain **Chapter 23:** Principles of wound healing **Chapter 24:** Pathophysiology and principles of varicose veins **Chapter 25:** Chronic venous insufficiency and leg ulceration: Principles and vascular biology **Chapter 26:** Pathophysiology and principles of management of the diabetic foot **Chapter 27:** Lymphoedema – Principles, genetics and pathophysiology **Chapter 28:** Graft materials past and future **Chapter 29:** Pathophysiology of vascular graft infections



BARR SMITH PRESS

An imprint of
The University of Adelaide Press